Reuters logo
BRIEF-FDA provides Cornerstone Pharmaceuticals approval to initiate pivotal study for CPI-613
2017年3月23日 / 下午2点34分 / 8 个月前

BRIEF-FDA provides Cornerstone Pharmaceuticals approval to initiate pivotal study for CPI-613

March 23 (Reuters) - Idt Corp

* FDA provides cornerstone pharmaceuticals approval to initiate pivotal study for CPI-613, its metabolism-directed anticancer compound Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below